Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954781 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2POLBAGTR1ABCG2PDK2 | |
| SCHEMBL4888374 | 0.87 | POLB (0.39) | SMN1; SMN2POLBABCG2PDK2NPC1 | |
| SCHEMBL9257119 | 0.84 | POLB (0.40) | SMN1; SMN2POLBABCG2PDK2NPC1 | |
| SCHEMBL14169541 | 0.83 | POLB (0.34) | SMN1; SMN2POLBAGTR1 | |
| SCHEMBL30743612 | 0.79 | ABCG2 (0.55) | SMN1; SMN2POLBAGTR1ABCG2NPC1 | |
| SCHEMBL16370823 | 0.78 | AGTR1 (0.43) | SMN1; SMN2POLBAGTR1ABCG2NPC1 | |
| SCHEMBL9429714 | 0.78 | ABCG2 (0.36) | SMN1; SMN2POLBAGTR1ABCG2NPC1 | |
| SCHEMBL4990435 | 0.78 | SMN1; SMN2 (0.36) | SMN1; SMN2POLBABCG2NPC1RAB9A | |
| SCHEMBL8402419 | 0.77 | POLB (0.40) | SMN1; SMN2POLBAGTR1ABCG2NPC1 | |
| SCHEMBL9033772 | 0.77 | AGTR1 (0.41) | SMN1; SMN2POLBAGTR1ABCG2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-7915425-B2 | Process for the preparation of losartan | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-03-29 | — | — | US | disclosed |
| US-7915425-B2 | Process for the preparation of losartan | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-03-29 | — | — | US | disclosed |
| US-20100222597-A1 | Process for the preparation of losartan | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-20100222597-A1 | Process for the preparation of losartan | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-20080132555-A1 | PREPARATION AND UTILITY OF SUBSTITUTED PHENYLTETRAZOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132555-A1 | PREPARATION AND UTILITY OF SUBSTITUTED PHENYLTETRAZOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132555-A1 | PREPARATION AND UTILITY OF SUBSTITUTED PHENYLTETRAZOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008067378-A2 | PREPARATION AND UTILITY OF SUBSTITUTED PHENYLTETRAZOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20070249839-A1 | Process for the Preparation of Losartan Potassium Form I | CADILA PHARMACEUTICALS LTD. (IN) | 2007-10-25 | — | — | US | disclosed |
| US-20070249839-A1 | Process for the Preparation of Losartan Potassium Form I | CADILA PHARMACEUTICALS LTD. (IN) | 2007-10-25 | — | — | US | disclosed |
| US-6245790-B1 | ANTIINFLAMMATORY AGENTS; GASTROINTESTINAL DISORDERS; SKN DISORDERS; BONE DISORDERS; MUSCLE RELAXANTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-12 | — | — | US | disclosed |
| EP-0989975-A1 | OXAZOLE COMPOUNDS USEFUL AS PGE2 AGONISTS AND ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
| WO-2000016760-A2 | NEW USE OF PROSTAGLANDIN E2 ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-30 | — | — | WO | disclosed |
| WO-1998055468-A1 | OXAZOLE COMPOUNDS USEFUL AS PGE2 AGONISTS AND ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132555-A1 | PREPARATION AND UTILITY OF SUBSTITUTED PHENYLTETRAZOLES | CYP3A7, CYP3A5, CYP2C19 | SMN1; SMN2 2795/4885POLB 1897/4885AGTR1 2103/4885 |
| US-20070249839-A1 | Process for the Preparation of Losartan Potassium Form I | AGTR1, REN, AGT | SMN1; SMN2 4434/4885POLB 3372/4885AGTR1 1/4885 |
| US-20100222597-A1 | Process for the preparation of losartan | AGT, ACE, AGTR1 | SMN1; SMN2 3914/4885POLB 1585/4885AGTR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.